Basiliximab shortage — IT supply status & alternatives

Basiliximab

ATC L04AC02

🇦🇺 AUST R 66740 · Novartis Pharmaceuticals Australia Pty Ltd

In supply · Australia

Simulect

In supply · 🇦🇺 Australia · short in🇮🇹 IT🇨🇦 CA🌐 TW

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

ATC level 5
Active ingredient (INN)	Basiliximab
Brand names	Simulect

ATC level 4	L04AC

Therapeutic category	Canonical INN head (inn_resolution)

Controlled substance	No

Marketing-authorisation holders	Novartis Pharmaceuticals Australia Pty Ltd

Registrations on file	1

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

FDA-approved products 🇺🇸 Drugs@FDA

Approved applications

Generic (ANDA)

Brand (NDA/BLA)

Mar 2001

Latest approval

Shortage status by regulator official notices

🇮🇹

Italy

AIFA · 1d ago

Critical

🇨🇦

Canada

HC · 2h ago

High

🌐

TFDA · just now

Medium

Verified timeline regulator events

🇨🇦 22 May 2026

high reported

🇮🇹 1 Apr 2024

critical reported

🌐 21 June 2023

medium reported

🌐 14 June 2023

medium reported

Sources official regulators

🌐

TFDA

verified just now

verify ↗

🇨🇦

verified 2h ago

verify ↗

🇮🇹

AIFA

verified 1d ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders1 registration · 1 MA holder

Product	Strength	Form	Market	MA holder	Status
SIMULECT basiliximab	20mg	—	🇦🇺 AU	Novartis Pharmaceuticals Australia Pty Ltd	Active

Mederti Drug Report

Generated 4 July 2026 · Australia market · 3 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.